Market Size in 2021 | Market Forecast in 2028 | CAGR (in %) | Base Year |
---|---|---|---|
USD 521.30 million | USD 655.81 million | 3.9% | 2021 |
FrequentlyAsked Questions
Causes including the growing senior population are influencing the market, rising need for eradicating radiation therapy-related adverse effects, rising usage of radiotherapy for recovery, rising number of clinical studies, and rising governmental and private investment.
According to the report, the global radiodermatitis market was worth USD 521.30 million in 2021 and is estimated to grow to USD 655.81 billion by 2028, with approximately 3.9 percent compound annual growth rate (CAGR) over the forecast period.
North America is anticipated to be the fastest growing region in the radiodermatitis market throughout the projected period. The rising prevalence of cancer-causing disorders along with the strong market share of Cardinal Health, 3M, and Mylan N.V., along with their cutting-edge product advancements would favorably affect the radiodermatitis market in North America throughout the study period.
Some of the main competitors dominating the global radiodermatitis market include - The 3M Company, Bayer Ag., Bausch Health Companies Inc., BMG Pharma S.P.A., Convatec Group PLC., Glaxosmithkline PLC, Helsinn Healthcare SA, Molnlycke Health Care AB, Mylan N.V., Stratpharma Ag, Smith & Nephew PLC.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed